- Acquisition of next-generation Kv7 channel activators for target indications including epilepsy, pain disorders and affective disorders
- BHV-7000 is the lead asset from Kv7 channel platform and is potentially a best-in-class potassium channel activator with a profile suggestive for low-dose efficacy, reduced GABA activity, and a wide therapeutic index
- Biohaven anticipates entering BHV-7000 into the clinic in 2022 initially for the treatment of focal epilepsy
PR Newswire
NEW HAVEN, Conn., Feb. 25, 2022